Table 3.
Frequency and proportion of cases of breast cancer recurrence and matched controls
| ERP+/TAM+ [n, (%)] | ERP−/TAM− [n, (%)] | |||
|---|---|---|---|---|
| cases | control | cases | controls | |
| Citalopram prescription | ||||
| Ever | 37 (10) | 35 (10) | 12 (5.3) | 14 (6.1) |
| Ever, 0 to <30%a | 24 (6.6) | 25 (6.8) | 7 (3.1) | 10 (4.4) |
| Ever, 30 to ≤60% | 6 (1.6) | 7 (1.9) | 1 (0.4) | 1 (0.4) |
| Ever, >60% | 7 (1.7) | 3 (0.8) | 4 (1.8) | 3 (1.3) |
| Never | 329 (90) | 331 (90) | 216 (95) | 214 (94) |
| Other SSRI (ever exposed) | ||||
| Fluoxetine | 5 (1.4) | 7 (1.9) | 2 (0.9) | 4 (1.8) |
| Paroxetine | 6 (1.6) | 4 (1.1) | 1 (0.4) | 5 (2.2) |
| Sertraline | 13 (3.6) | 15 (4.1) | 6 (2.6) | 4 (1.8) |
| Other SSRI or CYP2D6 inhibitorc | ||||
| Ever | 103 (28) | 95 (26) | 53 (23) | 54 (24) |
| Never | 263 (72) | 271 (74) | 175 (77) | 174 (76) |
| Diagnosis yearb | ||||
| 1985–1993 | 33 (9.0) | 34 (9.3) | 13 (5.7) | 11 (4.8) |
| 1994–1996 | 96 (26) | 96 (26) | 78 (34.2) | 75 (33) |
| 1997–2001 | 237 (65) | 236 (65) | 137 (60) | 142 (62) |
| Age at diagnosis | ||||
| 35–44 | 18 (4.9) | 18 (4.9) | 41 (18) | 33 (15) |
| 45–54 | 93 (25) | 85 (23) | 100 (44) | 85 (37) |
| 55–64 | 191 (52) | 178 (49) | 61 (27) | 75 (33) |
| 65–70 | 64 (18) | 85 (23) | 26 (11) | 35 (15) |
| Menopausal status at diagnosisb | ||||
| Premenopausal | 42 (12) | 42 (12) | 83 (36) | 83 (36) |
| Postmenopausal | 324 (89) | 324 (89) | 145 (64) | 145 (64) |
| County of residence at diagnosisb | ||||
| Funen | 61 (17) | 61 (17) | 47 (21) | 47 (21) |
| South Jutland | 41 (11) | 41 (11) | 29 (13) | 29 (13) |
| Ribe | 7 (1.9) | 7 (1.9) | 9 (3.9) | 9 (3.9) |
| Vejle | 38 (10) | 38 (10) | 43 (19) | 43 (19) |
| Ringkøbing | 13 (3.6) | 13 (3.6) | 4 (1.8) | 4 (1.8) |
| Aarhus | 83 (23) | 83 (23) | 42 (18) | 42 (18) |
| Viborg | 33 (9.0) | 33 (9.0) | 17 (7.5) | 17 (7.5) |
| North Jutland | 90 (25) | 90 (25) | 37 (16) | 37 (16) |
| UICC tumor stage at diagnosisb | ||||
| Stage I | 14 (3.8) | 14 (3.8) | 34 (15) | 34 (15) |
| Stage II | 148 (40) | 148 (40) | 111 (49) | 111 (49) |
| Stage III | 204 (56) | 204 (56) | 83 (36) | 83 (36) |
| Histologic grade | ||||
| Grade I | 59 (16) | 89 (24) | 19 (8.3) | 13 (5.7) |
| Grade II | 157 (43) | 158 (43) | 83 (36) | 67 (29) |
| Grade III | 78 (21) | 45 (12) | 90 (40) | 90 (40) |
| Missing | 72 (20) | 74 (20) | 36 (16) | 58 (25) |
| Surgery type | ||||
| Breast conserving surgery | 53 (15) | 63 (17) | 42 (18) | 46 (20) |
| Mastectomy | 313 (86) | 303 (83) | 186 (82) | 182 (80) |
| Radiation therapy | ||||
| Yes | 159 (43) | 161 (44) | 108 (47) | 104 (46) |
| No | 207 (57) | 205 (56) | 115 (50) | 106 (47) |
| Missing | 5 (2.2) | 18 (7.9) | ||
| Tamoxifen protocol | ||||
| One year | 76 (21) | 59 (16) | Not | Not |
| Two years | 50 (14) | 62 (17) | Applicable | Applicable |
| Five years | 240 (66) | 245 (67) | ||
| Systemic adjuvant chemotherapy | ||||
| Yes | 34 (9.3) | 39 (11) | 175 (77) | 150 (66) |
| No | 332 (91) | 327 (89) | 53 (23) | 78 (34) |